Novartis could take $750M hit for recalls; Greek pharmacist becomes medicine hunter;

> The recent Novartis ($NVS) recall of OTC medicines could cost $560 million to $750 million in lost sales and productivity, a Wall Street analyst says. More

> A pharmacist in Athens "spends hours each day pleading with drugmakers, wholesalers and colleagues to hunt down medicines." Story

> NantWorks LLC plans to spend $85 million to renovate Pfizer's ($PFE) Terra Haute, IN, manufacturing plant for production of critical-care injectable and cancer drugs. News

> The shortage of calcitriol, manufactured by Abbott Labs ($ABT), is now resolved. FDA listing

> A 69-acre, 1,300-job AstraZeneca ($AZN) manufacturing plant in Loughborough, U.K., closed in December, is being marketed "more broadly" after talks with Chinese pharma investors appear to have stalled. Article

> Andrea Zobelhas joined Marken as a senior director, responsible for the company's network of clinical trial supply depots when qualified. Release

> Some 150 staff members of Almac's Clinical Services business unit have moved into a new 30,000-square-foot building, consolidating services for clients in more than 100 countries. News

> A team effort by the World Bank, the U.K. Department for International Development, and the Small Industries Development Bank of India has helped more than 200 Indian drugmakers become export-ready GMP practitioners. Article

> Catalent Pharma Solutions is remodeling a former GE Healthcare building in Wisconsin and is planning to move in by year's end, vacating its current site. Story

Suggested Articles

A biotech that worked with a nutritional products maker on the API for its clinical-stage radiation drug, is buying all of the manufacturing know-how.

Merck KGaA is selling a manufacturing site and its Allergopharma allergy drug business as it focuses on newer meds.

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S.